Cabenuva is administered monthly as an injectable. This can replace HIV patients’ current antiretroviral regimen, which requires them to take multiple pills several times a day, cautiously scheduled around meals.
“This approval will allow some patients the option of receiving once-monthly injections in lieu of a daily oral treatment regimen,” John Farley MD, the director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said in a news release. “Having this treatment available for some patients provides an alternative for managing this chronic condition.”
The approval was granted to ViiV Healthcare, a U.K.-based drugmaker with its U.S. headquarters in Research Triangle Park, N.C.
More articles on pharmacy:
Fauci: US rejoining WHO means it will join Covax
New Jersey governor blames CVS, Walgreens for slow vaccine rollout
California says halted Moderna vaccine batch is safe
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
